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Abstract
Cancer chemotherapy has been shown to induce long-term skeletal side effects such as osteoporosis and fractures;
however, there are no preventative treatments. This study investigated the damaging effects of anti-metabolite
methotrexate (MTX) subcutaneous injections (0.75 mg/kg BW) for five days and the potential protective benefits of daily
oral gavage of fish oil at 0.5 mL/100 g BW (containing 375 mg of n-3 PUFA/100 g BW), genistein (2 mg/100 g BW), or their
combination in young adult rats. MTX treatment alone significantly reduced primary spongiosa height and secondary
spongiosa trabecular bone volume. Bone marrow stromal cells from the treated rats showed a significant reduction in
osteogenic differentiation but an increase in adipogenesis ex vivo. Consistently, stromal cells had significantly higher mRNA
levels of adipogenesis-related proliferator activator activated receptor-c (PPAR-c) and fatty acid binding protein (FABP4).
MTX significantly increased the numbers of bone-resorbing osteoclasts and marrow osteoclast precursor cell pool while
significantly enhancing the mRNA expression of receptor activator for nuclear factor kappa B ligand (RANKL), the RANKL/
osteoprotegerin (OPG) ratio, interleukin-6 (IL-6), and tumor necrosis factor-a (TNF-a) in the bone. Supplementary treatment
with fish oil and/or genistein significantly preserved trabecular bone volume and osteogenesis but suppressed MTX-
induced adipogenesis and increases in osteoclast numbers and pro-osteoclastogenic cytokine expression. Thus, Fish oil and/
or genistein supplementation during MTX treatment enabled not only preservation of osteogenic differentiation, osteoblast
number and bone volume, but also prevention of MTX treatment-induced increases in bone marrow adiposity,
osteoclastogenic cytokine expression and osteoclast formation, and thus bone loss.
Citation: Raghu Nadhanan R, Skinner J, Chung R, Su Y-W, Howe PR, et al. (2013) Supplementation with Fish Oil and Genistein, Individually or in Combination,
Protects Bone against the Adverse Effects of Methotrexate Chemotherapy in Rats. PLoS ONE 8(8): e71592. doi:10.1371/journal.pone.0071592
Editor: Xing-Ming Shi, Georgia Regents University, United States of America
Received June 7, 2013; Accepted July 8, 2013; Published August 12, 2013
Copyright:  2013 Raghu Nadhanan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This project was funded in part by project grants from Channel-7 Children’s Research Foundation of South Australia and National Health and Medical
Research Council (NHMRC) Australia. RRN is a recipient of University of South Australia PhD scholarship. CJX is a senior fellow of NHMRC Australia. The funders had
no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Cory.Xian@unisa.edu.au
Introduction
Both clinical and animal studies have reported that chemother-
apy causes adverse effects on bone, negatively impacting on bone
remodeling and bone mass [1,2,3,4,5,6,7]. Anti-metabolite meth-
otrexate (MTX) is a widely used chemotherapeutic agent in
treatment for acute lymphoblastic leukaemia (ALL), non-Hodg-
kin’s lymphoma, and at lower doses for rheumatoid arthritis and
psoriatic arthritis [8]. It competes for the folate binding site of the
enzyme dihydrofolate reductase (DHFR), thus disrupting reduc-
tion of folic acid to tetrahydrofolic acid responsible for DNA
synthesis and cell replication [9,10]. In treatment of childhood
leukaemia, MTX has been shown to cause bone pain, osteopenia
and fractures [11,12]. Previous studies using rat models have
demonstrated that MTX decreases trabecular bone volume, which
is associated with increased adipogenesis, enhanced osteoclasto-
genesis, and decreased osteogenesis potential within the bone
marrow, and thus a lower osteoblast number but a higher
osteoclast density on the bone surface as well as a higher adipocyte
density in the bone marrow [1,3,13,14,15]. Despite these recent
findings, the underlying mechanisms for MTX chemotherapy-
induced bone loss and marrow require further investigations.
In addition, due to the increasing usage of anti-cancer drugs
among cancer patients, it is important to explore potential
supplementary treatments which might be useful in protecting
bone during cancer chemotherapy. Currently, there is a lack of
safe and cost effective treatments against chemotherapy-induced
bone loss. The available anti-resorptive therapies using bisphos-
phonates are known to reduce resorption, increase bone mass and
thus have some efficacy in preventing/reducing osteoporosis [16].
However, high costs involved in their administration and also the
tendency of forming brittle bones after a long-term usage has been
questioned lately [17,18]. Thus, in the search for supplementary
treatments which are safe and non-toxic to protect the bone during
cancer chemotherapy, cancer sufferers are increasingly turning to
alternative treatments including natural products (nutraceuticals)
for better bone health and improved life quality.
Population studies have shown that women consuming high
levels of soy products rich in isoflavone genistein and fish rich in
omega-3 polyunsaturated fatty acids (n-3 PUFA) have increased
bone mass and a lower risk of post-menopausal osteoporosis
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[19,20]. The n-3 PUFA eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA) abundant in fatty fish such as
salmon, menhaden and tuna or in their oils are known to have
significant anti-inflammatory properties and positive effects on
bone metabolism, possibly via suppressing pro-inflammatory
mediators like prostaglandin E2 (PGE2), IL-1, IL-6 and TNF-a,
which are known to promote osteoclastogenesis and increase bone
loss [21,22]. Both EPA and DHA have been shown to promote
bone specific alkaline phosphatase activity, osteoblastogenesis and
bone formation and suppress osteoclastogenesis and bone resorp-
tion [23,24,25,26], and thus increase bone density in older adults
and postmenopausal women [26,27,28].
Genistein, a phytoestrogen abundant in soybeans, tofu, tempeh
and soymilk, has been shown to have pharmacological properties
beneficial for human health including skeletal health [29].
Epidemiological studies have established that the Asian diet with
a high level of genistein leads to reduced rates of post-menopausal
osteoporosis [30,31]. Overall, genistein has been shown to
anabolically modulate bone cells and benefit bone by stimulating
protein synthesis, alkaline phosphatase release, differentiation of
osteoblasts [32,33], production of OPG (an osteoclastogenesis
inhibitor) by osteoblasts and bone formation [34,35]. Genistein has
also been shown to suppress the activation of protein phosphatases
and nuclear factor-kappa B (NF-kappa B) and Akt signaling
pathways, which are known to maintain a homeostatic balance
between cell survival and apoptosis, to inhibit osteoclast formation,
induce their apoptosis and to suppress bone resorption [32,33].
Some previous reports have indicated that consumption of
genistein benefited bone health while not causing significant
adverse effects on breast and uterus tissues [36,37,38].
However, it is unknown whether fish oil or genistein has any
efficacy in reducing chemotherapy-induced bone defects. Fish oil
and genistein individually have anti-inflammatory, anti-osteoclas-
togenic, pro-osteogenic, and anti-oxidant properties
[24,29,38,39,40,41]. However, it remains to be investigated
whether their combination use may further enhance these
beneficial effects on bone health and prevent bone loss caused
by chemotherapy. Using a rat model, the current study
investigated the damaging effects in osteogenesis, osteoclastogen-
esis and adipogenesis in long bones caused by MTX treatment and
examined the protective effects and potential action mechanisms
of supplementary treatments with fish oil and genistein (either
individually or in combination).
Materials and Methods
Animal Trial and Specimens
This study was approved by the Animal Ethics Committee of
SA Pathology/Central Northern Adelaide Health Service of South
Australia. Male Sprague-Dawley rats of approximately 6 weeks of
age were randomly allocated to eight groups receiving saline (Sal)
or MTX injections and oral gavage treatments with water (H2O),
fish oil (FO), genistein (Gen), or fish oil and genistein in
combination (FO+Gen). These 8 groups were: Normal control
(Sal+H2O), fish oil alone (Sal+FO), genistein alone (Sal+Gen),
FO+Gen alone (Sal+FO+Gen), MTX alone (MTX+H2O),
MTX+FO, MTX+Gen, and MTX+FO+Gen.
For one week prior to MTX or saline injection, rats were
pretreated by daily oral gavage with water at 0.5 mL/100 g BW,
fish oil alone at 0.5 mL/100 g BW (containing 375 mg of n-3
PUFA/100 g BW), genistein (2 mg/100 g BW) or a combination
of fish oil and genistein. Rats were then subcutaneously injected
once daily with saline or MTX at 0.75 mg/kg (dosage similar to
clinical therapeutic usage) [1,3] for 5 consecutive days (mimicking
the intensive induction phase of treatment for childhood acute
lymphoblastic leukaemia (ALL) [42]. Oral gavage treatment was
given throughout the whole period and ended one day before kill.
For specimen collection, rats were humanely killed by CO2
overdose on Day 9 (since the first MTX/saline injection) (a key
time point shown to have obvious damaging effects by MTX) as
described [3]. The fish oil used was ROPUFAH 75-EE (containing
42% EPA and 22% DHA as ethyl esters, and genistein was
BonisteinTM (99.6% pure synthetic genistein) (DSM Nutritional
Products, Kaiseraugst, Switzerland).
Peripheral blood collected in lithium-heparin tubes was used for
collecting plasma which was stored at 280uC. The proximal left
tibia was collected, fixed in 10% formalin for 24 h, decalcified in
Immunocal (Decal Corp, Tallman, NY) at 4uC, processed and
embedded in paraffin wax for collecting sections of 4 mm thick
mounted on positively charged SuperFrost Plus TM glass slides for
histological analysis. Metaphyseal bone (0.4 mm) from the right
tibia was obtained, snap frozen in liquid nitrogen and were stored
at 280˚C for gene expression studies. The remaining tibia, femurs,
and humerus were collected and used to obtain bone marrow cells
by removing both ends of bones, centrifuging at 0.9 RCF in a
microfuge at 4uC for 5 mins. The marrow cells (pooled to yield
one sample per rat) were purified by LymphoprepTM density
gradient to obtain the bone marrow mononuclear cells (BMMNC),
which were washed with phosphate buffered saline (PBS) and
resuspended in basal media consisting of basal minimum essential
medium (a-MEM) (Sigma, Sydney, NSW, Australia) containing
10% FBS (Invitrogen, Carlsbad, CA), 50 mg/mL Pen/Strep
(Invitrogen), 15 mM HEPES (Sigma) and 130 mM L-ascorbate
(Sigma) as described [1]. Upon plating out all cell assays (see
below), the remaining mononuclear cell suspension was plated into
T75 flasks and cultured with basal media at 37uC and 5% CO2.
Stromal cells (which adhere to the base of the flasks) were
maintained for approximately 10 days until 80% confluence, and
then collected and frozen at 280uC until RNA extraction for gene
expression studies.
Histomorphometric Analysis of Growth Plate and
Metaphysis
To examine the potential treatment effects on bone formation
or bone volume, haematoxylin and eosin (H&E)-stained proximal
tibial sections were used for morphometric measurements of
growth plate total heights, heights of primary spongiosa and bone
volume of primary and secondary spongiosa metaphyseal bone
using AnalySIS software [2,3]. Total height of the growth plate
and average primary spongiosa zonal height at the metaphysis
were measured parallel to the longitudinal axis of the tibial bone.
At the secondary spongiosa (1 mm below the primary-secondary
spongiosa transitional line), total areas and the areas of all
trabecular cores were measured, which were then used to calculate
the bone volume to total tissue volume fraction (BV/TV %) as
described [1,2,3,4,14].
Numbers of Bone Surface Osteoblasts and Osteoclasts
and Bone Marrow Adipocytes
Osteoblasts and osteoclasts are cells involved in bone formation
and bone resorption respectively; their densities on trabecular
bone surface were measured to assess treatment effects in bone.
Staining for tartrate-resistant acid phosphatase (TRAP, a marker
for osteoclasts) was performed using naphtal AS-BI phosphate
(Sigma) and a solution of pararosanilline and sodium nitrate as
described [7]. Osteoclasts (TRAP-positive cells containing at least
3 nuclei) along the trabecular surface were counted within primary
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spongiosa and secondary spongiosa and expressed as osteoclasts
per mm2 trabecular bone area. At both the primary and secondary
spongiosa on H&E stained sections, the osteoblast numbers
(mononuclear cuboidal shaped cells lining trabecular surface)
were also counted and expressed as total osteoblasts per mm2 of
trabecular bone area as described [2]. Adipocyte density was
determined at the lower secondary spongiosa bone marrow (cells/
mm2 marrow area) by measuring the average of adipocytes across
3 sequential images as described [15].
Colony Forming Unit Fibroblast (CFU-f) Assay and
Alkaline Phosphatase (ALP) Staining
To determine treatment effects on the size of osteoprogenitor
cell pool, a CFU-f assay followed by ALP staining was performed
as described [1,43]. Briefly, bone marrow cells were cultured at
16106 in 6-well tissue culture dishes with basal media (described
above) and were allowed to adhere and proliferate to form colonies
for 14 days with media changed twice a week. At the end of the
culture, cells were fixed with 10% formalin and stained for ALP
activity. Subsequently, plates were stained with toluidine blue
(Sigma) as an assessment of total numbers of colony formation.
ALP+ or toluidine+ colonies (containing more than 50 cells in a
cluster in each colony) were counted under a light microscope.
The numbers of ALP+ colonies were expressed as percentage of
total CFU-f colonies.
Mineralization Assay and Alizarin Red Staining
As means to assess the treatment effects on mineralization
capacity, bone marrow cells were plated out at a plating density of
26106 in a T25 filtered flasks with basal media for a week. For
initiation of mineralization, basal media was then replaced by
mineralization media containing basal media supplemented with
10 nM dexamethasone and 10 mM b–glycerolphosphate (Sigma)
and were cultured for an additional 11 days with media refreshed
twice per week. Mineralizing colonies was assessed upon alizarin
red staining with positive colonies (red nodules) counted, followed
by toluidine blue staining and expressed as a percentage of alizarin
red+ of total CFU-f colonies.
Ex-vivo Adipogenesis Assay and Nile Red Staining
To assess treatment effects on adipogenesis in the bone marrow,
bone marrow stromal cells were obtained as described above and
were cultured for 7 days in T25 flasks at a plating density of 26106
with normal basal media. For adipogenic induction, cells were fed
the basal medium supplemented with 1 uM dexamethasone
(Sigma), 0.5 mM methyl-isobutylxanthanine (Sigma) and
100 uM indomethacin (Sigma) for another 7 days as described
[15,44]. Nile red staining was used to identify adipogenic colonies
under fluorescence microscope (excitation 485 nm, emission
525 nm), followed by toluidine blue staining, and total adipogenic
colonies were expressed as percentage of Nile red+ of total CFU-f
colonies.
Ex-vivo Osteoclast Formation Assay and TRAP Staining
Treatment effects on osteoclastogenesis were analyzed using an
ex vivo osteoclast formation assay via the RANKL/M-CSF system
[1,45,46]. Bone marrow cells obtained from the rats were cultured
in a-MEM supplemented with 10% FBS, 50 mg/ml Pen/Strep
and 15 mM HEPES. Upon culturing overnight, non-adherent
hematopoietic cells were collected and were plated in 96-well trays
at a density of 36105 cells/well in triplicate, and cultured in the
above medium plus 10 ng/ml macrophage colony-stimulating
factor (M-CSF) (Peprotech, Rocky Hill, NJ). Starting from the
following day, 30 ng/ml of RANKL (Peprotech) was added into
this M-CSF-containing medium; and cells were maintained for 8
days with medium change once every 3 days. At the end of culture,
cells were fixed and stained for TRAP as described [1]. Numbers
of osteoclasts formed are presented as TRAP+ multinuclear cells/
mm2.
Quantitative RT-PCR Analysis of Gene Expression
For analyzing levels of expression of genes related to osteogenic
and adipogenic differentiation, total RNA was extracted from
bone marrow stromal cells (obtained and cultured as described
above) using RNAqueousH-Micro Kit (Ambion, Applied Biosys-
tems, Melbourne, Australia) and treated with DNAse using DNA-
free kit (Ambion). For examining treatment effects on expression of
pro-inflammatory cytokines and osteoclastogenesis regulatory
genes in bone, RNA was extracted from the metaphyseal bone
samples (obtained as described above) using Tri-reagent (Sigma)
[47]. cDNA synthesis from the RNA was done using an High
Capacity RNA to cDNA kit (Applied Biosystems). Quantitative
PCR assays were run on a 7500 Fast Real-Time PCR System
(Applied Biosystems) in duplicate using specific primers (Table 1)
[47] (ordered from Geneworks, Adelaide, SA, Australia). Relative
expression was calculated using the comparative Ct (22DCt)
method, with Cyclophilin A (Cyc A) as the endogenous control.
Multiplex Pro-inflammatory and Anti-inflammatory
Cytokine Assay
To examine treatment effects on plasma levels of pro-
inflammatory and anti-inflammatory cytokines, the Bio-Plex
ProTM magnetic bead-based multiplex rat cytokine assay kit
(Biorad, Hercules, CA) was specially customized and used to detect
IL-4, IL-10, IL-6, TNF-a and IL-1 in the plasma samples. Briefly,
the capture antibody–coupled beads were first incubated with
antigen standards or samples (in duplicate) followed by incubation
with biotinylated detection antibodies. After washing, the beads
were incubated with a reporter streptavidin-phycoerythrin conju-
gate (SA-PE). Following removal of excess SA-PE, the beads were
passed through the Bio-Plex array reader, which measures the
fluorescence of the bead and of the bound SA-PE. All washes were
performed using a Bio-Plex Pro wash station. Data acquisition was
Table 1. List of primers used in RT-PCR.
Gene Forward Primer (59-39) Reverse Primer (59-39)
IL-1 GTTTCCCTCCCTGCCCTCGAC GACAATGCTGCCTCGTGA
IL-6 CAGCGATGATGCACTGTCAGA CCAGGTAGAAACGGAACTCCA
IL-4 ACAAGTCTGGGGTTCTCGGTG CGGTGCAGCTTCTCAGTGAGTTC
IL-10 GGCCATTCCATCCGGGGTGA GAAATCGATGACAGCGTCGCAGC
TNF-a ATGGCCCAGACCCTCACACTCAGA CTCCGCTTGGTGGTTTGCTACGAC
RANK GGGAAAACGCTGACAGCTAATC GGTCCCCTGAGGACTCCTTATT
RANKL CCGTGCAAAGGGAATTACAAC GAGCCACGAACCTTACATCA
OPG CACAGCTCGCAAGAGCAAACT ATATCGCGTTGCACACTGCTT
OCN ATTCACCACCTTACTGCCCTCCTG GCTGGCCCTGACTGCATTCTG
CYC-A GAGCTGTTTGCAGACAAAGTTTC CCCTGGCACATGAATCCTGG
PPAR-c TCCTCCTGTTGACCCAGAGCAT AGCTGATTCCGAAGTTGGTGG
FABP 4 GGAATTCGATGAAATCACCCC TGGTCGACTTTCCATCCCACT
Osx GCTTTTCTGTGGCAAGAGGTTC CTGATGTTTGCTCAAGTGGTCG
Runx2 TCACAAATCCTCCCCAAGTGG GAATGCGCCCTAAATCACTGA
doi:10.1371/journal.pone.0071592.t001
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performed using Bio-Plex ManagerTM software 5.0 at high PMT
setting.
Statistics
Data are presented as means 6 SEM and were analysed by a
one-way analysis of variance (ANOVA) using GraphPad Prism 5
(GraphPad Software, San Diego, CA). When significance
(P,0.05) was achieved, a post hoc analysis of groups was performed
using a Tukey’s test. Histogram bars with differing letters denote
mean values which are significantly different from each other
(P,0.05).
Results
Treatment Effects on Primary Spongiosa Height and
Trabecular Bone Volume
Histomorphometric measurements revealed no significant
changes in the total height of the growth plate across the
treatment groups (P.0.05) (Fig. 1A). A significant reduction of
the primary spongiosa height was noted in the MTX alone group
when compared to the control (Sal+H2O) group (P,0.05) and
Sal+FO+Gen (P,0.01). All supplemented groups (MTX+FO,
MTX+Gen, MTX+FO+Gen) were considerably higher than the
MTX alone group and were not statistically different from the
Sal+H2O, although only MTX+Gen group was significantly
higher than the MTX alone group (P,0.05) (Fig. 1A–1D, 1F).
Measurements of the BV/TV (%) within the secondary spongiosa
revealed a significant reduction in MTX alone group compared to
Sal+H2O, Sal+FO, Sal+Gen and Sal+FO+Gen groups (P,0.001)
(Fig. 1A–1D, 1G). MTX+FO (P,0.01), MTX+Gen (P,0.05)
and MTX+FO+Gen (P,0.01) treatments had significantly pre-
served the bone volume, which was reduced by MTX alone
(Fig. 1G).
Treatment Effects on Osteoblast Numbers and
Osteogenic Differentiation Potential
At the secondary spongiosa, MTX alone treatment caused no
significant reductions in osteoblast numbers when compared to all
of the control groups, MTX+FO and MTX+Gen groups (P.0.05)
(Fig. 1H). However, osteoblast density was significantly preserved
in the MTX+FO+Gen group compared to the MTX alone group
(P,0.05). Ex vivo CFU-f assay plus ALP staining revealed a
significantly lower percentage of ALP+ CFU-f colonies formed by
the bone marrow stromal cells from the MTX alone group when
compared to Sal+H2O, Sal+FO, Sal+Gen (P,0.05) and Sal+-
FO+Gen (P,0.01) groups (Fig. 2A–2C). Compared to the MTX
alone group, the supplemented groups (MTX+FO, MTX+Gen
and MTX+FO+Gen) had significantly more ALP+ CFU-f colonies
(P,0.001, P,0.001, P,0.01 respectively) (Fig. 2C). The ability
of CFU-f colonies to mineralize was also determined in this
current study (by counting alizarin red-stained colonies) (Fig. 2D,
2E). It was revealed that, while MTX alone group did not
significantly produce fewer mineralizing colonies when compared
to all the saline-treated control groups (P.0.05), only MTX+Gen
group had a significantly more mineralizing colonies than MTX
alone group (P,0.05) (Fig. 2F).
Real time RT-PCR analyses of the mRNA expression levels of
osteogenic transcription factors Runx2 and Osx in bone marrow
stromal cells levels of Runx2 (Fig. 2G) and Osx (data not shown)
were not significantly affected in the MTX alone group when
compared to all of the other treatment groups (P.0.05).
Expression of bone matrix protein OCN in the stromal cells were
not significantly affected by the different treatments (P.0.05)
(Fig. 2H).
Treatment Effects on Adipocyte Numbers and
Adipogenic Differentiation
Histological measurements of adipocyte numbers at the
metaphyseal (secondary spongiosa) and diaphyseal junction area
revealed a significantly higher adipocyte number in the MTX
alone group compared to all of the control groups (P,0.001)
(Fig. 3A–3C). While fish oil supplementation (MTX+FO) tended
to prevent MTX-induced marrow adiposity (P.0.05 vs MTX
alone group), the MTX+FO group still had more adipocytes than
the Sal+H2O group (P,0.05) (Fig. 3C). However, genistein
supplementation (MTX+Gen) significantly suppressed MTX
treatment-induced increased adipocyte numbers (P,0.001 vs the
MTX alone group; P.0.05 vs Sal+ H2O group).
Consistently, ex vivo adipogenic differentiation assessment of the
bone marrow stromal cell samples revealed significantly more Nile
red+ colonies in cultures from the MTX alone group than the
control or supplement alone groups (P,0.001) (Fig. 3D–3F). All
the supplementary treatment groups (MTX+FO, MTX+Gen and
MTX+FO+Gen) had significantly fewer Nile red+ colonies in
comparison to MTX alone group (P,0.001), which had similar
levels as the control groups (P.0.05) (Fig. 3F).
Consistent with the finding of increased adipocyte formation
upon MTX treatment, expression of adipogenesis regulatory genes
PPAR-c and FABP4 in cultured bone marrow stromal cells was
significantly elevated in the MTX alone group compared to all of
the control groups (P,0.05) (Fig. 3G, 3H). All the supplementary
groups significantly attenuated the MTX-induced increased
expression of FABP4 (P,0.01 vs MTX alone group). MTX+FO
and MTX+FO+Gen (P,0.05 and P,0.01 respectively) treat-
ments also significantly suppressed MTX-induced increased
expression in PPAR-c (Fig. 3G, 3H).
Treatment Effects on Osteoclast Density and Formation
TRAP staining and histological measurement revealed that,
compared to the Sal+H2O control and all other control groups,
the MTX alone group displayed a significantly increased number
of osteoclasts on trabecular surface at the metaphysis (P,0.05)
(Fig. 4A–4C). However, the MTX-induced increase in osteoclast
density was significantly attenuated in all three supplement groups
(MTX+FO, MTX+Gen and MTX+FO+Gen, P,0.01, P,0.001,
P,0.001, respectively, compared to MTX alone group). Consis-
tent with the histological observations, ex vivo osteoclastogenesis
assay with isolated bone marrow cells showed that there were
significantly more TRAP+ multinucleated cells formed from the
bone marrow from the MTX alone group than from all control
groups (Sal+H2O, Sal+FO, Sal+Gen, and Sal+FO+Gen)
(P,0.001) (Fig. 4D–4F). All supplemented groups (MTX+FO,
MTX+Gen and MTX+FO+Gen) had significantly suppressed the
osteoclastogenic potential induced by MTX (P,0.001 compared
to MTX alone group) (Fig. 4F).
mRNA Expression of Pro-inflammatory Cytokines and
Osteoclastogenesis-related Molecules
Quantitative RT-PCR expression analyses of pro-inflammatory
cytokines and osteoclastogenesis regulatory molecules showed that,
consistent with the enhanced osteoclastogenesis and osteoclast
density at the metaphysis induced by MTX treatment, MTX
alone treated rats had significantly higher mRNA expression of
RANKL when compared to rats treated with Sal+H2O (P,0.05),
Sal+FO (P,0.05) and Sal+Gen (P,0.01) (data not shown).
However, mRNA gene expression of OPG was not significantly
different between the rats treated with MTX alone and with Sal+
H2O (P.0.05). MTX+FO group had a significant upregulation in
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the OPG levels in comparison to groups treated with MTX+ H2O,
Sal+FO, Sal+Gen, Sal+FO+Gen (P,0.001 respectively) and
MTX+FO+Gen (P,0.05) (data not shown). As a result, there
was a significant upregulation in the RANKL/OPG expression
ratio in the MTX alone group compared to all the control groups
(P,0.001) (Fig. 5A). All supplementary treatments (MTX+FO,
MTX+Gen and MTX+FO+Gen) significantly attenuated the
RANKL/OPG ratio compared to the MTX alone group
(P,0.001) (Fig. 5A). Similarly, expression of TNF-a was
significantly upregulated in the MTX alone group compared to
all control groups (Sal+H2O, Sal+Gen, Sal+FO+Gen, P,0.001;
and Sal+FO, P,0.05) (Fig. 5B). However, this upregulation was
significantly suppressed in all the supplementary treatment groups
(MTX+FO, MTX+Gen and MTX+FO+Gen, P,0.001,
P,0.001, P,0.01, respectively, compared with MTX alone
group) (Fig. 5B).
IL-6 gene expression was also significantly induced with MTX
alone treatment compared to Sal+H2O control (P,0.01) (Fig. 5C);
however, all supplementary treatments did not significantly
counteract MTX-induced increase in IL-6 expression (P.0.05
compared to MTX alone group) (Fig. 5C). Expression of IL-1 was
shown not to be affected significantly by MTX treatment nor by
Figure 1. Effects of MTX with or without fish oil (FO) and/or genistein (Gen) supplementation on growth plate, primary and
secondary spongiosa. Paraffin sections of the tibial metaphysis region (PS = Primary spongiosa, SS = Secondary spongiosa, which are separated
by a dashed line) of (A) a normal rat, (B) a MTX+H2O treated rat showing reduced height of primary spongiosa and. metaphyseal bone volume, (C) a
MTX+FO treated rat, and (D) a MTX+Gen treated rat. (E) Growth plate total height (mm). (F) Primary spongiosa height (mm). (G) Secondary spongiosa
BV/TV (%). (H) Secondary spongiosa osteoblast/mm2 trabecular bone area. Values are means6 SEM; n = 7–8 for all groups. Labelled means without a
common letter differ (P,0.05).
doi:10.1371/journal.pone.0071592.g001
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all the supplementary treatments, although it tended to be elevated
in MTX alone group (P.0.05 compared to Sal+H2O group) and
MTX+Gen and MTX+FO+Gen groups tended to suppress this
tendency (P.0.05) (data not shown). Levels of mRNA expression
in bone of anti-inflammatory cytokines IL-4 (Fig. 6A) and IL-10
(Fig. 6B) were also analysed which showed no significant
differences across the treatment groups (P.0.05).
Levels of Pro- or Anti- Inflammatory Cytokines in Plasma
Samples
A multiplex cytokine ELISA assay with the plasma samples
revealed no significant alterations in the level of pro-inflammatory
cytokine IL-6 across the treatment groups (P.0.05) (Fig. 5D).
Interestingly, while MTX treatment alone did not significantly
reduce the plasma anti-inflammatory cytokine IL-4 level (P.0.05),
fish oil and/or genistein supplementation in MTX-treated rats
reversed this trend to the extent that levels of plasma IL-4 were
significantly greater in MTX+FO and MTX+FO+Gen groups
than in the MTX alone group (P,0.05) (Fig. 6C). Plasma levels of
pro-inflammatory cytokine IL-10 were not significantly altered in
all of the treatment groups (P.0.05) (Fig. 6D). Analyses of other
cytokines such as IL-1, TNF-a and RANKL in plasma samples did
not reveal obvious differences among treatment groups (P.0.05)
(data not shown).
Discussion
MTX chemotherapy has been shown to cause osteopenia, bone
pain and fracture [11,12,48,49], for which the underlying
mechanisms remain unclear and there is a lack of preventative
therapeutic options. The current study further defined the effects
of MTX treatment in rats and also explored the potential
protective effects of oral consumption of anti-inflammatory fish oil
and anti-oxidant and osteotrophic genistein, either individually or
Figure 2. Effects of MTX alone or with supplementary treatment with (FO) and/or genistein (Gen) on osteogenic differentiation
potential of bone marrow stromal cells isolated from treated rats. Images of a culture well showing bone marrow stromal cell-derived CFU-f
colonies stained positive for alkaline phosphatase (ALP, arrows) of (A) a control rat and (B) a MTX alone treated rat on day 9 post the first MTX
injection. (C) Treatment effects on size of osteoprogenitor cell pool in bone marrow. Mineralizing colonies stained positive by Alizarin Red (arrows) of
(D) a control rat and (E) a MTX alone treated rat. (F) Ex vivo mineralization assay with bone marrow cells isolated from rats. RT-PCR relative mRNA
expression of (G) Runx2 and of (H) bone matrix protein osteocalcin (OCN) assessed in bone marrow stromal cells of treated rats (relative to
Cyclophilin-A). Labelled means without a common letter differ (P,0.05).
doi:10.1371/journal.pone.0071592.g002
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in combination, against MTX-induced bone loss. Consistent with
the previous observation [1,3,14], the current study revealed that
MTX treatment significantly decreased the primary spongiosa
height and secondary spongiosa trabecular bone volume. Al-
though the primary spongiosa region of the metaphysis is derived
from the growth plate, these observed changes in the metaphysis
might be due to the observed significant increase in osteoclast
recruitment and resorption. The significantly increased osteoclast
numbers and thus resorptive activity while no significant
differences in the density of osteoblasts at both primary and
secondary spongiosa would have contributed to the significant
reduction in the primary spongiosa height and secondary
spongiosa bone volume. However, it was clear that supplemen-
tation with fish oil and/or genistein had significantly protected the
height of the primary spongiosa and preserved the bone volume at
the metaphysis which were reduced by the MTX alone treatment.
As discussed below, this might be due to the ability of these
supplements to not only suppress osteoclastogenesis/osteoclast
numbers but also to preserve the bone marrow osteogenesis/bone
surface osteoblast numbers.
Since studies have shown that a shift in differentiation of bone
marrow mesenchymal stem or stromal cells (MSCs) towards the
adipocyte lineage over the osteoblast lineage can ultimately lead to
bone loss [15,50], the current study investigated the treatment
effects on the MSC lineage commitment in the bone marrow.
Although MTX treatment did not cause any significant reduction
in osteoblast numbers on the trabecular surface, it caused a
statistically significant suppression in osteogenic differentiation
potential as exhibited by ALP+ CFU-f and mineralizing assays
within the bone marrow stromal cell population. However, no
statistically significant reduction was observed in mRNA gene
expression of osteogenic transcription factors Runx2 and OCN in
bone marrow stromal cells. Supplementary treatment with fish oil
and/or genistein however prevented the reduction in osteogenic
differentiation induced by MTX as revealed by ALP+-CFU-f and
mineralizing assays. This was also consistent with the preservation
of osteoblast numbers on the trabecular surface. Our findings
suggest that fish oil and/or genistein preferentially enhanced the
differentiation of the marrow stromal cells down the osteogenic
lineage, thus contributing to the preserved bone mass during
MTX treatment. Our findings are consistent with the previous
findings of osteotrophic activity of n-3 PUFA and genistein in
animals or post-menopausal women with estrogen deficiency
[25,51,52,53,54].
Figure 3. Effects of MTX with or without (FO) and/or genistein (Gen) supplementation on bone marrow adiposity and adipogenesis
potential ex vivo. H&E-stained sections of tibial lower secondary spongiosa in a (A) control rat and (B) a MTX alone treated rat. (C) Adipocyte
numbers on bone histology sections. (D) Nile Red-stained images of cultures showing adipocyte formation in an ex vivo adipogenesis assay with
bone marrow stromal cells of a control rat and (E) a MTX+H2O treated rat. (F) Quantification of Nile Red+ colonies in an ex vivo adipogenesis assay
from bone marrow cells of treated rats. RT-PCR relative gene expression analysis of adipogenesis related genes (G) PPARc and (H) FABP4 assessed in
the isolated bone marrow stromal cells. Labelled means without a common letter differ (P,0.05).
doi:10.1371/journal.pone.0071592.g003
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Figure 4. Effects of MTX with or without (FO) and/or genistein (Gen) supplementation on osteoclastogenesis potential. Images of
TRAP-stained tibial metaphysis (arrows pointing multinucleated TRAP-positive osteoclasts) of (A) a control rat and (B) a MTX alone treated rat on day
9 post the first MTX injection showing more osteoclasts present. (C) Average osteoclast numbers at tibial primary and secondary spongiosa. Images
of TRAP positively-stained cells formed (arrows pointing multinucleated TRAP-positive osteoclast-like cells) in an ex vivo osteoclastogenesis assay of
(D) a control rat and (E) a MTX alone treated rat on day 9 post the first MTX injection showing more osteoclasts formed. (F) Ex vivo osteoclast
formation from bone marrow cells isolated from treated rats. Labelled means without a common letter differ (P,0.05).
doi:10.1371/journal.pone.0071592.g004
Figure 5. Effects of MTX with or without (FO) and/or genistein (Gen) supplementation on expression of osteoclastogenesis-
regulatory or related genes. Levels of mRNA expression in metaphysis bones of treated rats as quantitated by real time RT-PCR: (A) RANKL/OPG
ratio, (B) TNF-a, and (C) IL-6. (D) Levels (pg/mL) of circulating IL-6 protein in plasma samples of treated rats as measured by multiplex cytokine assay.
Labelled means without a common letter differ (P,0.05).
doi:10.1371/journal.pone.0071592.g005
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Consistent with findings in a previous study [15], while reducing
the osteogenic potential, MTX caused an increased marrow
adiposity with a greater adipocyte number in the bone marrow.
Consistent with the increased adipogenesis after MTX treatment,
the current study also exhibited a significant upregulation of
adipogenesis-related genes, FABP4 and PPAR-c, in bone marrow
stromal cells isolated from the treated rats. Together, the current
and the previous studies [15,44] indicate that the increased
adipogenesis and reduced osteogenesis within the bone marrow of
MTX treated rats reflect a selective differentiation of stromal
progenitor cells down an adipogenic pathway in the expense of
osteogenesis. Consistent with this, a clinical study showed that
patients with acute myeloid leukaemia (AML) exhibited increased
fat cell formation within the bone marrow immediately after
intensive chemotherapy [55]. Furthermore, the current study
showed that fish oil and/or genistein supplementation had
stimulated osteogenesis while concurrently inhibiting MTX-
induced adipogenesis in the bone and bone marrow as revealed
by the histological, ex vivo adipogenesis culture and PPAR-c and
FABP4 gene expression studies. Our findings with the MTX
chemotherapy setting are consistent with previous observations
that these supplements have the ability to suppress expression of
adipogenic transcription factor PPAR-c and adipogenic differen-
tiation of bone marrow stromal cells in vitro [56,57,58,59].
Although the underlying action mechanisms remain to be studied,
our study has demonstrated the ability of fish oil and/or genistein
to promote osteogenesis while attenuating MTX-induced adipo-
genesis, thus contributing to preserving bone volume and
preventing marrow adiposity.
In the current study, a significant increase in the numbers of
osteoclast at metaphysis and enhanced osteoclastogenesis in the
bone marrow were observed in the MTX alone group, which were
consistent with previous findings [1,46,60,61]. In the current
study, as mentioned earlier, the osteoblast numbers were only
slightly affected in the metaphysis by the MTX treatment; thus the
significant increase in osteoclast numbers in the MTX treated
group would likely have contributed to the reduced bone volume.
This observation was consistent with another study involving
prolonged use of low dose MTX, in which a reduced bone density
was observed to be associated with an increased osteoclast number
[62]. In the current study, supplementary treatment with fish oil
and/or genistein was found to significantly prevent MTX
treatment-induced increased osteoclast presence on bone surface
and osteoclastogenesis in the bone marrow, suggesting that fish oil
and/or genistein have an anti-osteoclastic property and may
prevent osteoclast formation and bone loss during MTX
chemotherapy. Our anti-osteoclastogenesis observation with fish
oil and/or genistein with the MTX chemotherapy setting were
consistent with anti-osteoclastogenic property of these supplements
in estrogen deficiency setting in rats [24,33].
Osteoclasts differentiate from the monocyte/macrophage cell
lineage under the control of M-CSF and RANKL as well as
promotion from some pro-inflammatory cytokines [63]. A recent
study has demonstrated that MTX treatment can create an
inflammatory microenvironment in bone that coincided with
increased osteoclast formation and numbers [46]. In addition, an
increase in serum levels of IL-8 and TNF-a has been found in
patients subjected to chemotherapy drugs like epirubicin, vincris-
tine, cyclophosphamide, etoposide and prednisone [64,65,66].
The current study has also examined treatment effects on
expression of RANKL, inhibitor OPG and a number of pro-
inflammatory cytokines that are known to enhance osteoclast
formation, number and activity. It was found that, accompanying
a significant increase in osteoclast presence on bone surface and
osteoclastogenesis after MTX treatment, significantly increased
expression of RANKL but decreased expression in OPG (thus a
Figure 6. Effects of MTX with or without (FO) and/or genistein (Gen) supplementation on expression of anti-inflammatory
cytokines IL-4 and IL-10. Levels of mRNA expression in metaphysis bones of treated rats as quantitated by real time RT-PCR: (A) IL-4 and (B) IL-10.
Protein levels (pg/mL) of circulating (C) IL-4 and (D) IL-10 in plasma samples of treated rats as measured by multiplex cytokine assay. Labelled means
without a common letter differ (P,0.05).
doi:10.1371/journal.pone.0071592.g006
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significantly higher RANKL/OPG ratio) were noted in the MTX
treated group, suggesting MTX chemotherapy modulates the key
osteoclastogenic signal. In addition, consistent with findings in a
recent study [46], mRNA expression of osteoclastogenic cytokines
TNF-a and IL-6 within the bone was increased IL-6 protein levels
were elevated in the plasma. In vitro studies have revealed that
TNF-a, IL-1 and IL-6 are capable of inducing active resorption by
mature osteoclasts [63,67]. These data indicate that MTX
treatment may create an inflammatory or osteoclastogenic
microenvironment in the bone promoting osteoclast formation
and activity. Consistent with the ability of fish oil and/or genistein
in inhibiting MTX-induced osteoclast formation and bone
resorption in this study, these supplements blunted MTX-induced
elevated RANKL/OPG ratio and expression of IL-6 and TNF-a.
Although the exact mechanism of action of these supplements in
suppressing osteoclastogenesis still requires further investigation,
rodent and human studies in estrogen deficiency or non-
challenged settings have also shown the ability of n-3 PUFAs
and genistein to suppress IL-6, IL-1 and TNF-a expression and/or
to lower RANKL/OPG ratio, thus attenuating osteoclast forma-
tion and activity [29,32,40,54,68,69,70,71]. Similarly, a clinical
study has shown that fish oil supplementation in rheumatoid
arthritis patients was associated with decreased production of IL-1
and TNF-a [72]. Therefore, fish oil and genistein in the current
study were shown to suppress MTX treatment-induced expression
of the pro-inflammatory cytokines and RANKL/OPG ratio,
which may have contributed to reduced osteoclast differentiation
and reduced bone resorption in the supplemented rats.
Previously, lack of anti-inflammatory cytokines IL-4 and IL-10
has been shown to lead to accelerated bone loss [73]. A previous
study has shown that at the completion of chemotherapy
treatment for bowel cancer involving Folfox chemotherapy
(combination of 5-Fluroruracil, Folic acid and Oxaliplatin), levels
of IL-4 and IL-10 were reduced in plasma [74]. In the current
study, MTX did not affect mRNA expression of IL-4 and IL-10;
and only fish oil supplementation modestly affected IL-4 plasma
levels and none of the other supplementary groups had any effects
on IL-10 plasma levels. Our current study suggests that MTX
chemotherapy, apart from causing an osteoclastogenic and pro-
inflammatory condition in the bone, did not significantly lower the
expression levels of anti-inflammatory cytokines (IL-4 and IL-10),
and fish oil and/or genistein supplementation was not found to
affect the levels of these anti-inflammatory cytokines.
Previous studies have shown that omega-3 fatty acid-derived
lipid mediators, known as resolvins and protectins, may play an
important role in resolving inflammation since they have potent
anti-inflammatory properties [75,76]. Osteoclast mediated bone
resorption is often a result of increased inflammation and studies
have demonstrated that both resolvins and protectins inhibit
inflammation-induced bone resorption and directly modulate
osteoclast differentiation and prevent bone resorption, providing
a mechanism by which the n-3 PUFAs protect against bone loss
[75,77]. However, it remains to be investigated whether chemo-
therapy with fish oil in this study would alter the profile or relative
abundance of lipid mediators of pro-inflammatory as opposed to
anti-inflammatory/proresolving lipid mediators in the bone, bone
marrow and in the circulation. It may be possible that these lipid
mediators might have promoted resolution of inflammation by
suppressing production of inflammatory/pro-osteoclastogenic cy-
tokines and promoted production of anti-inflammatory cytokines
in this study. On the other hand, genistein, having an anti-
inflammatory property, has been shown to inhibit inflammatory
transcription factor nuclear factor kappa B (NF-kB) activation
(known to be important for osteoclast formation, function and
survival). Genistein inhibits RANKL-induced I-kB degradation
and NF-kB nuclear translocation and hence inhibiting differen-
tiation of osteoclasts [28]. In addition, genistein has been shown to
directly suppress TNF-a-induced osteoclastogenesis and bone loss
via suppression of c-fos expression in osteoclast precursors, and
this suppression has been proposed to prevent nuclear accumu-
lation of nuclear factor of activated T cells (NFATc1), a key
regulator of osteoclast formation [54]. Further studies are required
to investigate the exact mechanisms of action of n3-PUFAs and
genistein in attenuating or counteracting MTX chemotherapy-
induced inflammatory condition, osteoclast formation and bone
resorption during MTX chemotherapy.
In summary, this study examined the effects of dietary
supplement with fish oil and/or genistein on long bones in rats
subjected to MTX chemotherapy. MTX induces an inflammatory
condition, increases osteoclast formation and stimulates adipogen-
esis at the expense of osteogenesis, thus leading to bone loss.
Supplementation with fish oil and/or genistein conserves the bone
and prevents MTX chemotherapy-induced bone loss by suppress-
ing osteoclastogenesis and stimulating osteogenesis while concur-
rently inhibiting adipogenesis in bone marrow. No additive or
synergistic protection was observed when fish oil and genistein
were administered in combination in this current study, although
two previous studies have shown that genistein and fish oil
additively induced parameters of bone structure and increased
bone mass synergistically in an ovariectomy-induced bone loss
model [78,79]. Despite this, the promising effects of fish oil and
genistein, shown in the current study, suggest that their therapeutic
potential in preventing MTX chemotherapy-induced bone loss
warrants further evaluation. Further studies are required to
elucidate the action mechanisms involved and the optimal doses
of these supplements required in preventing chemotherapy-
induced bone loss, including in models of longer-term chemo-
therapy or with other/multiple chemotherapy drugs.
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